Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Subsequent event (Details)

v3.26.1
Subsequent event (Details)
Feb. 04, 2026
Y
shares
$ / shares
Oct. 15, 2025
USD ($)
$ / shares
Dec. 31, 2025
USD ($)
Renal Anti-Fibrotic Therapeutic Program      
Subsequent events      
Consideration   $ 3,000,000  
Issue price | $ / shares   $ 0.86  
Cash finders' fee, percentage   5.00%  
Cash finders' fee, amount   $ 250,000  
Term of acquisition from execution of term sheet   90 days  
Termination fees   $ 50,000  
Deferred acquisition costs     $ 293,803
Deferred cash finder fees     $ 200,000
Offering | Director      
Subsequent events      
Options to purchase common shares issued | shares 20,000    
Share price | $ / shares $ 0.69    
Term of options granted | Y 5